查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1829857

2025年乳癌診斷全球市場報告

Breast Cancer Diagnostics Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，乳癌診斷市場呈現強勁成長勢頭，市場規模從2024年的46.8億美元增加至2025年的50億美元，複合年成長率達7.0%。這段歷史性時期的成長可歸因於意識提升宣傳活動、篩檢活動、乳房X光攝影檢查、技術進步、基因檢測以及多學科方法。

預計未來幾年乳癌診斷市場規模將強勁成長，2029年將達到68.1億美元，複合年成長率為8.0%。預測期內的成長可歸因於個人化醫療、液態切片、3D乳房X光攝影（斷層合成）、人工智慧和機器學習、遠端醫療以及遠距會診。預測期內的主要趨勢包括影像技術、個人化醫療、液態切片以及人工智慧和機器學習的進步。

乳癌是一種以乳房細胞不受控制地生長為特徵的疾病，常導致腫塊的形成。乳癌診斷設備旨在識別並確認乳房組織中是否存在癌性生長。

乳癌診斷的主要類別包括各種診斷方法，例如影像技術、切片檢查、基因組檢測、血液檢測和其他相關方法。切片切片檢查是從身體中取出組織或細胞樣本進行後續實驗室檢測的過程，是乳癌病例中採用的主要診斷技術之一。這些診斷技術包括螢光原位雜合反應(FISH)、比較基因組雜合反應(CGH) 和免疫組織化學 (IHC)。乳癌可分為各種亞型，包括 BRCA乳癌、ER/PR乳癌、HER2乳癌、EGFR 突變和其他突變特異性乳癌。乳癌診斷進一步分為電離和非電離乳癌成像技術。這些診斷服務的最終用戶包括醫院和診所、癌症研究中心、診斷實驗室和門診手術中心。

2025年春季，美國關稅突然上調及其引發的貿易摩擦對醫療設備產業產生了重大影響，尤其對用於診斷影像設備的進口零件、手術用不銹鋼和一次性塑膠製品產生了重大影響。由於醫院和診所抵制漲價，製造商面臨利潤壓力。監管挑戰進一步加劇了形勢，因為由於關稅而更換供應商通常需要醫療設備重新認證，導致市場准入延遲。為此，企業正在透過雙重採購關鍵零件、增加標準化產品的國內生產以及加快尋找更具成本效益的材料來降低風險。

本研究報告是商業研究公司 (The Business Research Company) 新報告系列的一部分，該系列提供乳癌診斷市場統計數據，例如全球市場規模、區域佔有率、乳癌診斷市場佔有率的競爭對手、詳細的乳癌乳癌細分市場、市場趨勢和商業機會，以及您在乳癌診斷行業取得成功所需的數據。本乳癌診斷市場研究報告對該行業的現狀和未來趨勢進行了詳細分析，為您提供所需的一切觀點。

未來五年8.0%的預測成長率，較我們先前對該市場的預測略有下降0.2%。這一下降主要源自於美國與其他國家之間關稅的影響。這可能會透過對來自法國和英國等主要地區的免疫組織化學試劑和數位病理掃描儀徵收關稅直接影響美國，從而可能導致檢測成本上升和治療計劃延遲。由於互惠關稅以及貿易緊張局勢和限制加劇對全球經濟和貿易的負面影響，這種影響也將更加廣泛地顯現。

預計乳癌診斷市場的成長將受到乳癌發病率上升的推動。乳癌是最常見的癌症，每年影響約210萬名女性，並導致女性癌症相關死亡人數最多，預計將推動對診斷設備的需求。早期發現對於改善乳癌預後和降低死亡率至關重要。例如，美國癌症協會於2022年1月報告稱，2022年美國女性預計將新增287,850例浸潤性乳癌病例和51,400例美國原位癌病例，其中43,250例乳癌相關死亡病例。因此，乳癌發生率的上升預計將推動乳癌診斷市場的發展。

政府針對乳癌的措施和資金有望促進乳癌診斷市場的成長。政府透過採取措施和提供財務支持，在推動乳癌研究、預防和治療方面發揮著至關重要的作用。這些計畫旨在提高人們對乳癌的認知，透過篩檢和乳房X光攝影服務促進早期發現，並為貧困社區提供接受乳癌檢測和治療的財務支持。在 2022-23 年預算中，澳洲政府衛生署撥款 4,070 萬美元，用於提高各種癌症檢測和篩檢服務的可近性，其中 970 萬美元專門用於乳癌篩檢。因此，政府的措施和資金籌措努力正在推動乳癌診斷市場向前發展。

乳癌診斷市場的關鍵趨勢是技術的不斷進步，從而推動了乳癌新診斷技術的發展。一項值得注意的創新是3D乳房X光攝影（也稱為乳房斷層合成），它從不同角度拍攝乳房的多張影像並建立3D模型。該領域技術創新的一個例子是印度健康科技公司Niramai於2022年9月推出的Thermalytix。 Thermalytix是一種自動化乳癌篩檢和診斷工具，它結合了熱成像和人工智慧，以增強乳癌的檢測和診斷。

乳癌診斷市場的關鍵參與者正在積極開發基於人工智慧的尖端設備，旨在提高診斷準確性並推動市場收益。人工智慧乳癌診斷設備利用人工智慧演算法分析複雜的醫療數據並提供寶貴的診斷見解和建議。透過應用機器學習和資料處理技術，這些設備可以實現高度準確和高效的疾病識別。例如，英國生技公司 Digistain 於 2022 年 12 月推出了一款人工智慧乳癌診斷工具，準確率超過 99%。該技術經過臨床研究和同行評審的檢驗，不僅可以加快診斷速度，還可以增強治療決策。它有可能大幅減少等待時間、降低成本、實現個人化風險評估，並在某些情況下消除化療的需要。透過應用機器學習和專有光學掃描，該設備可以識別傳統方法經常忽略的複雜模式，提供經過大量患者樣本驗證的高度個人化風險評估。

2024年7月，美國醫療科技公司Hologic以3.1億美元收購了Endomagnetics Ltd.。此次收購將整合Endomag創新的無線立體定位和淋巴追蹤技術，並增強Hologic的乳房外科產品組合。總部位於英國的Endomagnetics Ltd.專注於先進的乳癌診斷解決方案，包括組織定位和淋巴追蹤技術。

乳癌診斷市場的主要參與者包括雅培實驗室、Myriad Genetics、Hologic、飛利浦、FUJIFILM Holdings、通用電氣醫療、賽默飛世爾科技、西門子、NanoString Technologies、GammaMedica、Aurora Imaging Technology、Dillon Technologies、Exact Sciences、F. Hoffmann-La Roche、Aurora Imaging Technology、Dillon Technologies、Exact Sciences、F. Hoffmann-Top、Aurora、Moran Roche、Mr. GmbH、bioTheranostics Inc.、Bio-Rad Laboratories Inc.、Illumina Inc.、Biocept Inc.、Epigenomics AG、阿斯利康公司、Quest Diagnostics Incorporated、安捷倫科技公司、Cepheid、Guardant Health Inc.、Invitae Corporation、Natera Inc.、Geneo） Veracyte Inc.。

2024年，北美是乳癌診斷市場最大的地區。亞太地區是乳癌診斷產業的第二大地區。乳癌診斷市場報告涵蓋亞太地區、西歐、東歐、北美、南美、中東和非洲。

寬頻網路服務市場報告涵蓋的國家包括澳洲、巴西、中國、法國、德國、印度、印尼、日本、俄羅斯、韓國、英國、美國、加拿大、義大利和西班牙

乳癌診斷市場涵蓋用於乳癌診斷的分析儀、試劑和其他設備的銷售。市場價值包括服務供應商銷售或包含在其服務產品中的相關商品的價值。僅包括企業之間交易或銷售給最終消費者的商品和服務。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球乳癌診斷：PESTEL分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 最終用途產業分析
  • 全球乳癌診斷市場：成長率分析
  • 全球乳癌診斷市場表現：規模與成長，2019-2024
  • 全球乳癌診斷市場預測：規模與成長，2024-2029年，2034年
  • 全球乳癌診斷：總目標市場（TAM）

第6章 市場細分

  • 全球乳癌診斷市場類型、表現及預測（2019-2024、2024-2029、2034）
  • 影像學
  • 切片檢查
  • 基因組檢測
  • 血液檢查
  • 其他類型
  • 全球乳癌診斷市場（依技術、績效及預測），2019-2024 年、2024-2029 年、2034 年
  • 螢光原位雜合反應（FISH）
  • 比較基因組雜合反應（CGH）
  • 免疫組織化學（IHC）
  • 其他技術
  • 全球乳癌診斷市場（按癌症類型、表現和預測），2019-2024 年、2024-2029 年、2034 年
  • BRCA乳癌
  • ER和PR乳癌
  • HER2乳癌
  • 乳癌EGFR突變檢測
  • 其他癌症類型
  • 全球乳癌診斷市場（按診斷類型、表現和預測），2019-2024 年、2024-2029 年、2034 年
  • 電離乳房成像技術
  • 非電離成像技術
  • 全球乳癌診斷市場（按最終用戶、績效和預測），2019-2024 年、2024-2029 年、2034 年
  • 醫院和診所
  • 癌症研究中心
  • 診斷實驗室
  • 門診手術中心
  • 全球乳癌診斷市場：按影像（類型）細分、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 乳房X光檢查
  • 超音波影像
  • 磁振造影（MRI）
  • 正子斷層掃描（PET）
  • 斷層合成
  • 全球乳癌診斷市場：依切片檢查類型、績效及預測細分，2019-2024 年、2024-2029 年、2034 年
  • 針吸切片
  • 芯針切片
  • 細針抽吸切片檢查（FNA）
  • 立體定位切片檢查
  • 全球乳癌診斷市場：按基因組測試類型、表現和預測細分，2019-2024 年、2024-2029 年、2034 年
  • Oncotype DX
  • 媽媽印花
  • PAM50
  • BRCA1或2檢測
  • 全球乳癌診斷市場：按血液檢測類型、表現和預測細分，2019-2024 年、2024-2029 年、2034 年
  • 液態生物檢體
  • 循環腫瘤DNA（ctDNA）檢測
  • 循環性腫瘤細胞（CTC）檢測
  • 全球乳癌診斷市場：按類型、其他、績效和預測細分，2019-2024 年、2024-2029 年、2034 年
  • 荷爾蒙受體檢測
  • HER2檢測
  • 基因突變檢測

第7章 區域和國家分析

  • 全球乳癌診斷市場：按地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球乳癌診斷市場：依國家、績效及預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章：西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章：俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 乳癌診斷市場：競爭格局
  • 乳癌診斷市場：公司簡介
    • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Hologic Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Koninklijke Philips NV Overview, Products and Services, Strategy and Financial Analysis
    • Fujifilm Holdings Corporation Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • GE Healthcare
  • Thermo Fisher Scientific Inc.
  • Siemens AG
  • NanoString Technologies Inc.
  • Gamma Medica Inc.
  • Aurora Imaging Technology Inc.
  • Dilon Technologies Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Micrima Limited
  • Provista Diagnostics Inc.
  • Leica Biosystems Nussloch GmbH
  • bioTheranostics Inc.
  • Bio-Rad Laboratories Inc.
  • Illumina Inc.

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章：高潛力市場國家、細分市場與策略

  • 2029年乳癌診斷市場：提供新機會的國家
  • 2029年乳癌診斷市場：細分領域帶來新機會
  • 2029年乳癌診斷市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章 附錄

簡介目錄
Product Code: r32425u

Breast cancer is a medical condition characterized by the uncontrolled proliferation of cells within the breast, often leading to the formation of lumps. Breast cancer diagnostic devices are designed for the purpose of identifying and confirming the presence of cancerous growth within the breast tissue.

Key categories within breast cancer diagnostics include various diagnostic methods such as imaging techniques, biopsies, genomic testing, blood tests, and other relevant approaches. Biopsy, a process involving the removal of tissue or cellular samples from the body for subsequent laboratory testing, is one of the primary diagnostic techniques employed in breast cancer cases. The technologies utilized for these diagnostic procedures encompass Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC) techniques, along with others. Breast cancer exhibits diverse types, including BRCA breast cancer, ER and PR breast cancer, HER2-positive breast cancer, EGFR mutation test breast cancer, and additional variants. Breast cancer diagnostics are further categorized into ionizing breast imaging technologies and non-ionizing imaging technologies. The end-users of these diagnostic services encompass hospitals and clinics, cancer research centers, diagnostic laboratories, as well as ambulatory surgical centers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The breast cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides breast cancer diagnostics market statistics, including breast cancer diagnostics industry global market size, regional shares, competitors with a breast cancer diagnostics market share, detailed breast cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer diagnostics industry. This breast cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The breast cancer diagnostics market size has grown strongly in recent years. It will grow from $4.68 billion in 2024 to $5 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to awareness and screening campaigns, mammography screening, technological advancements, genetic testing, multidisciplinary approach.

The breast cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $6.81 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to personalized medicine, liquid biopsies, 3d mammography (tomosynthesis), ai and machine learning, telemedicine and remote consultations. Major trends in the forecast period include advancements in imaging technologies, personalized medicine, liquid biopsies, ai and machine learning.

The forecast of 8.0% growth over the next five years indicates a slight reduction of 0.2% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through tariffs on immunohistochemistry reagents and digital pathology scanners, sourced from key regions such as France and the UK, which could lead to higher laboratory testing costs and potential delays in treatment planning.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growth of the breast cancer diagnostics market is expected to be driven by the increasing incidence of breast cancer. With breast cancer being the most prevalent form of cancer, affecting approximately 2.1 million women annually and resulting in the highest number of cancer-related deaths among women, the demand for diagnostic equipment is set to rise. Early detection is paramount in improving the prognosis and reducing the mortality rate associated with breast cancer. For example, in January 2022, the American Cancer Society reported an estimated 287,850 new cases of invasive breast cancer and 51,400 cases of DCIS in women in the United States for 2022, with an expected 43,250 breast cancer-related fatalities. Hence, the escalating incidence of breast cancer is projected to fuel the breast cancer diagnostics market.

Government initiatives and funding for breast cancer are poised to contribute to the growth of the breast cancer diagnostics market. Government support, through initiatives and financial backing, plays a crucial role in advancing breast cancer research, prevention, and treatment. These programs aim to raise awareness, promote early detection through screening and mammography services, and provide financial aid for underserved communities undergoing breast cancer testing and treatment. In the budget for 2022-23, the Australian Government Department of Health allocated $40.7 million to improve the accessibility of testing and screening services for various cancer types, including a dedicated $9.7 million for breast cancer screening. Consequently, government initiatives and funding initiatives are propelling the breast cancer diagnostics market forward.

In the breast cancer diagnostics market, a significant trend is the continuous advancement in technology, which has led to the development of new diagnostic techniques for breast cancer. One notable innovation is 3D mammography, also known as breast tomosynthesis, which captures multiple images of the breast from various angles and constructs a 3-D model. An example of technological innovation in this field is the introduction of Thermalytix by Niramai, an Indian Health-Tech company, in September 2022. Thermalytix is an automated breast cancer screening and diagnostic tool that combines thermal imaging with artificial intelligence to enhance breast cancer detection and diagnosis.

Key players in the breast cancer diagnostics market are actively engaged in the development of cutting-edge AI-based devices designed to improve diagnostic accuracy and drive market revenues. AI breast cancer diagnostic devices leverage artificial intelligence algorithms to analyze complex medical data and offer valuable diagnostic insights and recommendations. By applying machine learning and data processing techniques, these devices can deliver highly accurate and efficient disease identification. For example, Digistain, a biotech company based in the United Kingdom, launched an AI breast cancer diagnostic tool in December 2022, boasting an accuracy rate of over 99%. This technology, validated through clinical studies and peer reviews, not only expedites diagnoses but also enhances treatment decisions. It holds the potential to significantly reduce waiting times, lower costs, and enable personalized risk assessment, potentially eliminating the need for chemotherapy in some cases. Through the application of machine learning and proprietary optical scans, this device can identify intricate patterns that traditional methods may overlook, providing highly personalized risk evaluations validated with a substantial patient sample.

In July 2024, Hologic Inc., a US-based healthcare technology company, acquired Endomagnetics Ltd. for $310 million. This acquisition allows Hologic to strengthen its breast surgery portfolio by integrating Endomag's innovative wireless localization and lymphatic tracing technologies. Endomagnetics Ltd., based in the UK, specializes in advanced breast cancer diagnostic solutions, including technologies for tissue localization and lymphatic tracing.

Major companies operating in the breast cancer diagnostics market include Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Epigenomics AG, AstraZeneca plc, Quest Diagnostics Incorporated, Agilent Technologies Inc., Cepheid, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Oncocyte Corporation, PerkinElmer Inc., Sysmex Corporation, Veracyte Inc.

North America was the largest region in the breast cancer diagnostics market in 2024. Asia-Pacific was the second largest region in the breast cancer diagnostics industry. The regions covered in the breast cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the broadband internet services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The breast cancer diagnostics market consists of sales of instruments such as analyzer, reagents and others that are used for the diagnosis of breast cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Breast Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on breast cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for breast cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The breast cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Imaging; Biopsy; Genomic Tests; Blood Tests; Other Types
  • 2) By Technology: Fluorescent In Situ Hybridization (FISH); Comparative Genomic Hybridization (CGH); Immunohistochemical (IHC); Other Technologies
  • 3) By Cancer Type: BRCA Breast Cancer; ER And PR Breast Cancer; HER 2 Breast Cancer; EGFR Mutation Test Breast Cancer; Other Cancer Types
  • 4) By Diagnostic Type: Ionizing Breast Imaging Technologies; Non-ionizing Imaging Technologies
  • 5) By End Users: Hospitals And Clinics; Cancer Research Centers; Diagnostic Laboratories; Ambulatory Surgical Centers
  • Subsegments:
  • 1) By Imaging: Mammography; Ultrasound Imaging; Magnetic Resonance Imaging (MRI); Positron Emission Tomography (PET); Tomosynthesis
  • 2) By Biopsy: Needle Biopsy; Core Needle Biopsy; Fine Needle Aspiration Biopsy (FNA); Stereotactic Biopsy
  • 3) By Genomic Tests: Oncotype DX; MammaPrint; PAM50; BRCA1 Or 2 Testing
  • 4) By Blood Tests: Liquid Biopsy; Circulating Tumor DNA (ctDNA) Tests; Circulating Tumor Cells (CTCs) Tests
  • 5) By Other Types: Hormone Receptor Tests; HER2 Tests; Genetic Mutation Testing
  • Companies Mentioned: Abbott Laboratories; Myriad Genetics Inc.; Hologic Inc.; Koninklijke Philips N.V.; Fujifilm Holdings Corporation; GE Healthcare; Thermo Fisher Scientific Inc.; Siemens AG; NanoString Technologies Inc.; Gamma Medica Inc.; Aurora Imaging Technology Inc.; Dilon Technologies Inc.; Exact Sciences Corporation; F. Hoffmann-La Roche Ltd; Micrima Limited; Provista Diagnostics Inc.; Leica Biosystems Nussloch GmbH; bioTheranostics Inc.; Bio-Rad Laboratories Inc.; Illumina Inc.; Biocept Inc.; Epigenomics AG; AstraZeneca plc; Quest Diagnostics Incorporated; Agilent Technologies Inc.; Cepheid; Guardant Health Inc.; Invitae Corporation; Natera Inc.; NeoGenomics Laboratories Inc.; Oncocyte Corporation; PerkinElmer Inc.; Sysmex Corporation; Veracyte Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Breast Cancer Diagnostics Market Characteristics

3. Breast Cancer Diagnostics Market Trends And Strategies

4. Breast Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Breast Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Breast Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Breast Cancer Diagnostics Market Growth Rate Analysis
  • 5.4. Global Breast Cancer Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Breast Cancer Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Breast Cancer Diagnostics Total Addressable Market (TAM)

6. Breast Cancer Diagnostics Market Segmentation

  • 6.1. Global Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Imaging
  • Biopsy
  • Genomic Tests
  • Blood Tests
  • Other Types
  • 6.2. Global Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Fluorescent In Situ Hybridization (FISH)
  • Comparative Genomic Hybridization (CGH)
  • Immunohistochemical (IHC)
  • Other Technologies
  • 6.3. Global Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • BRCA Breast Cancer
  • ER And PR Breast Cancer
  • HER 2 Breast Cancer
  • EGFR Mutation Test Breast Cancer
  • Other Cancer Types
  • 6.4. Global Breast Cancer Diagnostics Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ionizing Breast Imaging Technologies
  • Non-ionizing Imaging Technologies
  • 6.5. Global Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals And Clinics
  • Cancer Research Centers
  • Diagnostic Laboratories
  • Ambulatory Surgical Centers
  • 6.6. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Imaging, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Mammography
  • Ultrasound Imaging
  • Magnetic Resonance Imaging (MRI)
  • Positron Emission Tomography (PET)
  • Tomosynthesis
  • 6.7. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Biopsy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Needle Biopsy
  • Core Needle Biopsy
  • Fine Needle Aspiration Biopsy (FNA)
  • Stereotactic Biopsy
  • 6.8. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Genomic Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oncotype DX
  • MammaPrint
  • PAM50
  • BRCA1 Or 2 Testing
  • 6.9. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Blood Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Liquid Biopsy
  • Circulating Tumor DNA (ctDNA) Tests
  • Circulating Tumor Cells (CTCs) Tests
  • 6.10. Global Breast Cancer Diagnostics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hormone Receptor Tests
  • HER2 Tests
  • Genetic Mutation Testing

7. Breast Cancer Diagnostics Market Regional And Country Analysis

  • 7.1. Global Breast Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Breast Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Breast Cancer Diagnostics Market

  • 8.1. Asia-Pacific Breast Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Breast Cancer Diagnostics Market

  • 9.1. China Breast Cancer Diagnostics Market Overview
  • 9.2. China Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Breast Cancer Diagnostics Market

  • 10.1. India Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Breast Cancer Diagnostics Market

  • 11.1. Japan Breast Cancer Diagnostics Market Overview
  • 11.2. Japan Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Breast Cancer Diagnostics Market

  • 12.1. Australia Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Breast Cancer Diagnostics Market

  • 13.1. Indonesia Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Breast Cancer Diagnostics Market

  • 14.1. South Korea Breast Cancer Diagnostics Market Overview
  • 14.2. South Korea Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Breast Cancer Diagnostics Market

  • 15.1. Western Europe Breast Cancer Diagnostics Market Overview
  • 15.2. Western Europe Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Breast Cancer Diagnostics Market

  • 16.1. UK Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Breast Cancer Diagnostics Market

  • 17.1. Germany Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Breast Cancer Diagnostics Market

  • 18.1. France Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Breast Cancer Diagnostics Market

  • 19.1. Italy Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Breast Cancer Diagnostics Market

  • 20.1. Spain Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Breast Cancer Diagnostics Market

  • 21.1. Eastern Europe Breast Cancer Diagnostics Market Overview
  • 21.2. Eastern Europe Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Breast Cancer Diagnostics Market

  • 22.1. Russia Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Breast Cancer Diagnostics Market

  • 23.1. North America Breast Cancer Diagnostics Market Overview
  • 23.2. North America Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Breast Cancer Diagnostics Market

  • 24.1. USA Breast Cancer Diagnostics Market Overview
  • 24.2. USA Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Breast Cancer Diagnostics Market

  • 25.1. Canada Breast Cancer Diagnostics Market Overview
  • 25.2. Canada Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Breast Cancer Diagnostics Market

  • 26.1. South America Breast Cancer Diagnostics Market Overview
  • 26.2. South America Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Breast Cancer Diagnostics Market

  • 27.1. Brazil Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Breast Cancer Diagnostics Market

  • 28.1. Middle East Breast Cancer Diagnostics Market Overview
  • 28.2. Middle East Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Breast Cancer Diagnostics Market

  • 29.1. Africa Breast Cancer Diagnostics Market Overview
  • 29.2. Africa Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Breast Cancer Diagnostics Market Competitive Landscape And Company Profiles

  • 30.1. Breast Cancer Diagnostics Market Competitive Landscape
  • 30.2. Breast Cancer Diagnostics Market Company Profiles
    • 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Hologic Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Koninklijke Philips N.V. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Fujifilm Holdings Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Breast Cancer Diagnostics Market Other Major And Innovative Companies

  • 31.1. GE Healthcare
  • 31.2. Thermo Fisher Scientific Inc.
  • 31.3. Siemens AG
  • 31.4. NanoString Technologies Inc.
  • 31.5. Gamma Medica Inc.
  • 31.6. Aurora Imaging Technology Inc.
  • 31.7. Dilon Technologies Inc.
  • 31.8. Exact Sciences Corporation
  • 31.9. F. Hoffmann-La Roche Ltd
  • 31.10. Micrima Limited
  • 31.11. Provista Diagnostics Inc.
  • 31.12. Leica Biosystems Nussloch GmbH
  • 31.13. bioTheranostics Inc.
  • 31.14. Bio-Rad Laboratories Inc.
  • 31.15. Illumina Inc.

32. Global Breast Cancer Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Breast Cancer Diagnostics Market

34. Recent Developments In The Breast Cancer Diagnostics Market

35. Breast Cancer Diagnostics Market High Potential Countries, Segments and Strategies

  • 35.1 Breast Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Breast Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Breast Cancer Diagnostics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer